GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (OTCPK:CASBF) » Definitions » Total Long-Term Liabilities

CASBF (CanSino Biologics) Total Long-Term Liabilities : $175.29 Mil (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is CanSino Biologics Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. CanSino Biologics's Total Long-Term Liabilities for the quarter that ended in Dec. 2024 was $175.29 Mil.

CanSino Biologics Total Long-Term Liabilities Historical Data

The historical data trend for CanSino Biologics's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics Total Long-Term Liabilities Chart

CanSino Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only 40.43 70.87 183.79 201.61 175.29

CanSino Biologics Quarterly Data
Dec16 Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 184.56 201.61 188.77 160.93 175.29

CanSino Biologics Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

CanSino Biologics Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

CanSino Biologics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (OTCPK:CASBF) » Definitions » Total Long-Term Liabilities
Comparable Companies
HKSE:00570 HKSE:01558 HKSE:02005 HKSE:01681 HKSE:00460 HKSE:02186 HKSE:03613 HKSE:01349 HKSE:02877 HKSE:02561 ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA
Traded in Other Exchanges
06185:Hong Kong CJH:Germany 688185:China
Address
185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN
Website
https://www.cansinotech.com
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. Its products are Menhycia and Menphecia; Convidecia, Convidecia Air, and XBB.1.5 Variant; Ad5-EBOV; PCV13i; PBPV; and DTcP Infant. Its geographic areas are PRC and Overseas. It generates the majority of its revenue from the PRC.